Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses

Abstract Plasmodium falciparum apical membrane antigen 1 (PfAMA1) is a candidate malaria vaccine antigen expressed on merozoites and sporozoites. PfAMA1’s polymorphic nature impacts vaccine-induced protection. To address polymorphism, three Diversity Covering (DiCo) protein sequences were designed a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Edmond J. Remarque, Bart W. Faber, Roberto Rodriguez Garcia, Herman Oostermeijer, Sodiomon B. Sirima, Issa Nebie Ouedraogo, Leila Kara, Odile Launay, Sophie Houard, Odile Leroy, Clemens H. M. Kocken
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e1524004d78d492694c5cb74ad9afcd8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e1524004d78d492694c5cb74ad9afcd8
record_format	dspace
spelling	oai:doaj.org-article:e1524004d78d492694c5cb74ad9afcd82021-12-02T14:30:51ZAccelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses10.1038/s41541-021-00319-22059-0105https://doaj.org/article/e1524004d78d492694c5cb74ad9afcd82021-04-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00319-2https://doaj.org/toc/2059-0105Abstract Plasmodium falciparum apical membrane antigen 1 (PfAMA1) is a candidate malaria vaccine antigen expressed on merozoites and sporozoites. PfAMA1’s polymorphic nature impacts vaccine-induced protection. To address polymorphism, three Diversity Covering (DiCo) protein sequences were designed and tested in a staggered phase Ia/b trial. A cohort of malaria-naive adults received PfAMA1-DiCo adjuvanted with Alhydrogel® or GLA-SE and a cohort of malaria-exposed adults received placebo or GLA-SE adjuvanted PfAMA1 DiCo at weeks 0, 4 and 26. IgG and GIA levels measured 4 weeks after the third vaccination are similar in malaria-naive volunteers and placebo-immunised malaria-exposed adults, and have a similar breadth. Vaccination of malaria-exposed adults results in significant antibody level increases to the DiCo variants, but not to naturally occurring PfAMA1 variants. Moreover, GIA levels do not increase following vaccination. Future research will need to focus on stronger adjuvants and/or adapted vaccination regimens, to induce potentially protective responses in the target group of the vaccine.Edmond J. RemarqueBart W. FaberRoberto Rodriguez GarciaHerman OostermeijerSodiomon B. SirimaIssa Nebie OuedraogoLeila KaraOdile LaunaySophie HouardOdile LeroyClemens H. M. KockenNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Edmond J. Remarque Bart W. Faber Roberto Rodriguez Garcia Herman Oostermeijer Sodiomon B. Sirima Issa Nebie Ouedraogo Leila Kara Odile Launay Sophie Houard Odile Leroy Clemens H. M. Kocken Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses
description	Abstract Plasmodium falciparum apical membrane antigen 1 (PfAMA1) is a candidate malaria vaccine antigen expressed on merozoites and sporozoites. PfAMA1’s polymorphic nature impacts vaccine-induced protection. To address polymorphism, three Diversity Covering (DiCo) protein sequences were designed and tested in a staggered phase Ia/b trial. A cohort of malaria-naive adults received PfAMA1-DiCo adjuvanted with Alhydrogel® or GLA-SE and a cohort of malaria-exposed adults received placebo or GLA-SE adjuvanted PfAMA1 DiCo at weeks 0, 4 and 26. IgG and GIA levels measured 4 weeks after the third vaccination are similar in malaria-naive volunteers and placebo-immunised malaria-exposed adults, and have a similar breadth. Vaccination of malaria-exposed adults results in significant antibody level increases to the DiCo variants, but not to naturally occurring PfAMA1 variants. Moreover, GIA levels do not increase following vaccination. Future research will need to focus on stronger adjuvants and/or adapted vaccination regimens, to induce potentially protective responses in the target group of the vaccine.
format	article
author	Edmond J. Remarque Bart W. Faber Roberto Rodriguez Garcia Herman Oostermeijer Sodiomon B. Sirima Issa Nebie Ouedraogo Leila Kara Odile Launay Sophie Houard Odile Leroy Clemens H. M. Kocken
author_facet	Edmond J. Remarque Bart W. Faber Roberto Rodriguez Garcia Herman Oostermeijer Sodiomon B. Sirima Issa Nebie Ouedraogo Leila Kara Odile Launay Sophie Houard Odile Leroy Clemens H. M. Kocken
author_sort	Edmond J. Remarque
title	Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses
title_short	Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses
title_full	Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses
title_fullStr	Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses
title_full_unstemmed	Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses
title_sort	accelerated phase ia/b evaluation of the malaria vaccine candidate pfama1 dico demonstrates broadening of humoral immune responses
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e1524004d78d492694c5cb74ad9afcd8
work_keys_str_mv	AT edmondjremarque acceleratedphaseiabevaluationofthemalariavaccinecandidatepfama1dicodemonstratesbroadeningofhumoralimmuneresponses AT bartwfaber acceleratedphaseiabevaluationofthemalariavaccinecandidatepfama1dicodemonstratesbroadeningofhumoralimmuneresponses AT robertorodriguezgarcia acceleratedphaseiabevaluationofthemalariavaccinecandidatepfama1dicodemonstratesbroadeningofhumoralimmuneresponses AT hermanoostermeijer acceleratedphaseiabevaluationofthemalariavaccinecandidatepfama1dicodemonstratesbroadeningofhumoralimmuneresponses AT sodiomonbsirima acceleratedphaseiabevaluationofthemalariavaccinecandidatepfama1dicodemonstratesbroadeningofhumoralimmuneresponses AT issanebieouedraogo acceleratedphaseiabevaluationofthemalariavaccinecandidatepfama1dicodemonstratesbroadeningofhumoralimmuneresponses AT leilakara acceleratedphaseiabevaluationofthemalariavaccinecandidatepfama1dicodemonstratesbroadeningofhumoralimmuneresponses AT odilelaunay acceleratedphaseiabevaluationofthemalariavaccinecandidatepfama1dicodemonstratesbroadeningofhumoralimmuneresponses AT sophiehouard acceleratedphaseiabevaluationofthemalariavaccinecandidatepfama1dicodemonstratesbroadeningofhumoralimmuneresponses AT odileleroy acceleratedphaseiabevaluationofthemalariavaccinecandidatepfama1dicodemonstratesbroadeningofhumoralimmuneresponses AT clemenshmkocken acceleratedphaseiabevaluationofthemalariavaccinecandidatepfama1dicodemonstratesbroadeningofhumoralimmuneresponses
_version_	1718391222679109632

Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses

Ejemplares similares